FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Go back to FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage| Johnson & Johnson (NYSE: JNJ) | Delayed: 230.79 +2.40 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.39 | 52 Week High | $126.07 | |||
| Open | $228.95 | 52 Week Low | $94.28 | |||
| Day High | $231.45 | P/E | 47.98 | |||
| Day Low | $227.50 | EPS | $4.81 | |||
| Volume | 3,032,432 | |||||
